Filariasis, Lymphatic
Description
Lymphatic filariasis is caused primarily by adult
worms (filariae) that live in the lymphatic vessels. The female worms
release microfilariae that circulate in the peripheral blood and
are ingested by mosquitoes; thus, infected mosquitoes transmit the
infection from person to person. The two major species of filariae
that cause lymphatic disease in humans are Wuchereria bancrofti and Brugia
malayi.
Occurrence
Lymphatic filariasis affects an estimated 120 million
persons in tropical areas of the world, including sub-Saharan Africa,
Egypt, southern Asia, the western Pacific islands, the northeastern
coasts of South and Central America, and the Caribbean Islands.
Risk for Travelers
Short-term travelers to endemic areas are at low
risk for this infection. Travelers who visit endemic areas for extended
periods of time and who are intensively exposed to infected mosquitoes
can become infected. Most infections seen in the United States are
in immigrants from endemic countries.
Clinical Presentation
Most infections are asymptomatic, but the living
adult worm causes progressive lymphatic vessel dilation and dysfunction.
Lymphatic dysfunction leads to lymphedema of the leg, scrotum, penis,
arm, or breast, which can increase in severity as a result of recurrent
secondary bacterial infections. Tropical pulmonary eosinophilia is
a potentially serious progressive lung disease with nocturnal cough,
wheezing, and fever, resulting from immune hyperresponsiveness to
microfilaria in the pulmonary capillaries.
Prevention
No vaccine is available, nor has the effectiveness
of chemoprophylaxis been well documented. Protective measures include
avoidance of mosquito bites through the use of personal protection
measures (see
Protection against Mosquitoes and Other Arthropods).
Treatment
The drug of choice for treatment of travelers with W.
bancrofti or B. malayi infections is diethylcarbamazine
(DEC). DEC, which is available to U.S.-licensed physicians for
this purpose, can be obtained from the CDC Parasitic Diseases
Drug Service at 404-639-3670. (See Immunobiologics
Distributed by The Centers for Disease Control and Prevention from
the CDC Drug Service.) DEC kills circulating microfilaria and is
partially effective against the adult worms and tropical pulmonary
eosinophilia. Many patients with lymphedema are no longer infected
with the filarial parasite and do not benefit from antifilarial
drug treatment. For chronic manifestations of lymphatic filariasis,
such as lymphedema and hydrocele, specific lymphedema treatment
(including hygiene, skin care, physical therapy, and in some cases,
antibiotics) and surgical repair, respectively, are recommended.
Travelers should be advised to consult an infectious disease or
tropical medicine specialist.
— David
Addiss
|